Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.


Account Information Already have an account? Log in here

*
LEAVE THIS BLANK

Payment Information We Accept Visa, Mastercard, American Express and Discover

 

By selecting this, I agree to receive emails from fenix.group.


You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.

Provention Bio Teplizumab Adcom Pre-read Materials Posted

Here is a brief preview of this blast: FDA posted the pre-read materials for the upcoming teplizumab advisory committee meeting on May 27, 2021 at 9AM EST. Of note, it is believed this is the first time the intended marketed name for teplizumab, "Tzield," has been disclosed. While it remains to be seen, FENIX predicts a split adcom vote (10-7 favoring teplizumab) due to questions around the clinical meaningfulness of a 2-year delay in the context of the SAEs, including immunosuppression. Below, FENIX provides a brief overview of the key points the panel will consider as well as preliminary thoughts on the adcom.

About The Author

Matthew Maryniak

|
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.